Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Acetylsalicylic acid is standard for secondary cardiovascular prevention, but recurrent ischemic events persist.
• Intensified antithrombotic therapies reduce cardiovascular events but increase bleeding without improving mortality.
• Dual pathway inhibition offers a novel strategy for managing cardiovascular risk.

Purpose of the Study:

• To review the COMPASS trial results on dual pathway inhibition.
• To explain the superiority of dual pathway inhibition over single antiplatelet or anticoagulant therapy.
• To compare rivaroxaban plus aspirin with other antithrombotic regimens and guide clinical application.

Main Methods:

• Analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.
• Comparison of dual pathway inhibition (low-dose rivaroxaban plus aspirin) versus aspirin alone.
• Evaluation of major adverse cardiovascular events, limb events, mortality, and bleeding.

Main Results:

• Dual pathway inhibition reduced major adverse cardiovascular events by 24% and mortality by 18% compared to aspirin alone.
• Significant reductions were observed in major adverse limb events (47%) and overall mortality.
• Major bleeding increased by 70%, but fatal or intracranial bleeding did not increase.

Conclusions:

• Dual pathway inhibition with low-dose rivaroxaban and aspirin is superior to aspirin alone for secondary prevention in patients with coronary artery disease or peripheral arterial disease.
• This strategy effectively reduces ischemic events and mortality, offering a significant benefit-risk profile.
• Clinical application of COMPASS trial findings can optimize antithrombotic therapy in high-risk cardiovascular patients.